Skip to content

Teleflex

US · TFX #2082 by market cap Listed 1970
124.48 -0.26 -0.21%
Live - 5344 symbols - heartbeat 2s ago · 2026-10-08 08:19
Pre-market 124.07 -0.33%
After-hours 124.48 0.00%
Market cap
5.27B
P/B
1.82
EPS
-20.25
Reader sentiment Are you bullish or bearish on TFX?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.82 Cheap vs history 25th percentile
5-year average 2.42 · #15 of 51 in Medical Instruments & Supplies
P/E ratio -5.43 Cheap vs history 17th percentile
5-year average 26.31 · forward 26.04
P/S ratio 2.35 Cheap vs history 21st percentile
5-year average 3.40 · forward 2.29 · #22 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Teleflex (TFX) 5.27B -5.41 1.82 1.09%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value154.26 Economic moatNone UncertaintyMedium

Trading 23.9% below Morningstar's fair value estimate.

Fair value

Teleflex Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $154.26 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's balance sheet increases our estimated fair value. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 1.2, which sits in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.5, for example, sits in the top 30% globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:19:20 · For reference only, not investment advice and not tailored to your situation.